{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T15:25:57Z","timestamp":1748013957318},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,1,24]],"date-time":"2014-01-24T00:00:00Z","timestamp":1390521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The high cost of clotting factor concentrate (CFC) used to treat haemophilia and von Willebrand disease (VWD) attracts health plans\u2019 attention for cost management strategies such as disease management programmes (DMPs). In 2004, Indiana's high risk insurance health plan, the Indiana Comprehensive Health Insurance Association, in partnership with the Indiana Hemophilia and Thrombosis Center developed and implemented a DMP for beneficiaries with bleeding disorders. This report evaluates the effectiveness of the DMP 5\u00a0years post implementation, with specific emphasis on the cost of CFC and other medical expenditures by severity of disease. A pre\/post analysis was used. The main evaluation measures were total cost, total outpatient CFC IU dispensed and adjusted total outpatient CFC cost. Summary statistics and mean and median plots were calculated. Overall, 1000 non\u2010parametric bootstrap replicates were created and percentile confidence limits for 95% confidence intervals (CI) are reported. Mean emergency department (ED) visits and mean and median duration of hospitalizations are also reported. The DMP was associated with a significant decrease in mean annualized total cost including decreased CFC utilization and cost in most years in the overall group, and specifically in patients with severe haemophilia. Patients with mild and moderate haemophilia contributed little to overall programme expenditures. This specialty health care provider\u2010administered DMP exemplifies the success of targeted interventions developed and implemented through a health care facility expert in the disease state to curb the cost of specialty pharmaceuticals in conditions when their expenditures represent a significant portion of total annual costs of care.<\/jats:p>","DOI":"10.1111\/hae.12370","type":"journal-article","created":{"date-parts":[[2014,1,24]],"date-time":"2014-01-24T06:46:54Z","timestamp":1390546014000},"page":"519-526","source":"Crossref","is-referenced-by-count":11,"title":["A haemophilia disease management programme targeting cost and utilization of specialty pharmaceuticals"],"prefix":"10.1111","volume":"20","author":[{"given":"N.","family":"Duncan","sequence":"first","affiliation":[{"name":"Indiana Hemophilia &amp; Thrombosis Center Indianapolis IN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Roberson","sequence":"additional","affiliation":[{"name":"Indiana Hemophilia &amp; Thrombosis Center Indianapolis IN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lail","sequence":"additional","affiliation":[{"name":"Rho, Inc. Chapel Hill NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Donfield","sequence":"additional","affiliation":[{"name":"Rho, Inc. Chapel Hill NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Indiana Hemophilia &amp; Thrombosis Center Indianapolis IN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,1,24]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Kaiser Family Foundation (KFF).US Health Care Costs. Available athttp:\/\/www.kaiseredu.org\/Issue-Modules\/US-Health-Care-Costs\/Background-Brief.aspx#footnote6. Accessed March 2013."},{"key":"e_1_2_8_3_1","unstructured":"Centers for Medicare & Medicaid Services (CMS).National Health Expenditures 2010 Highlights. Available athttp:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/NationalHealthExpendData\/downloads\/highlights.pdf. Accessed March 2013."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.20.2.9"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.26.1.249"},{"key":"e_1_2_8_6_1","unstructured":"SahrR.Consumer Price Index (CPI) Conversion Factors to Convert to 2010 Dollars Using the CPI\u2010U\u2010X1 series which applies the post\u20101982 CIP to 1950\u20101982. Available athttp:\/\/oregonstate.edu\/cla\/polisci\/sites\/default\/files\/faculty-research\/sahr\/inflation-conversion\/pdf\/cv2010x.pdf. July 2011."},{"key":"e_1_2_8_7_1","first-page":"26","article-title":"Specialty pharmaceuticals: developing a management plan","volume":"10","author":"Willcutts D","year":"2002","journal-title":"Managed Care Quarterly"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.24.4.1117"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1355-0691.2004.00881.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01495.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02692.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.27.3.824"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.23.6.63"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2011.17.2.175"},{"issue":"4","key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"III24","DOI":"10.1097\/01.mlr.0000119395.13327.e9","article-title":"Strategies to control costs and quality: a focus on outcomes research for disease management","volume":"42","author":"Villagra V","year":"2004","journal-title":"Med Care"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7234.563"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1089\/109350703321908478"},{"key":"e_1_2_8_19_1","first-page":"670","article-title":"Evidence for the effect of disease management: is $1 billion a year a good investment?","volume":"13","author":"Mattke S","year":"2007","journal-title":"Am J Managed Care"},{"key":"e_1_2_8_20_1","volume-title":"Disease Management: Findings From Leading State Programs","author":"Wheatley B","year":"2002"},{"key":"e_1_2_8_21_1","volume-title":"Base SAS(r) 9.2 Procedures Guide: Statistical Procedures","author":"SAS Institute Inc.","year":"2010"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/109350704322918961"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhae.12370","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.12370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:06:58Z","timestamp":1695571618000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.12370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,24]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1111\/hae.12370"],"URL":"https:\/\/doi.org\/10.1111\/hae.12370","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,24]]}}}